Ovarian Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Ovarian Cancer Treatment market by Type of Cancer (Epithelial Ovarian Tumor, Ovarian Germ Cell Tumor, Ovarian Stomatal Tumor, Primary Peritoneal Carcinoma), by Drug Class (Chemotherapeutic Agents, Targeted Therapy Drugs, Immune System Modulators, Hormones), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Ovarian Cancer Treatment Market size was valued at 2.2 billion in 2021 and is expected to reach 3.6 billion by 2028, at a CAGR of 7.1% during the forecast period 2022 to 2028. Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer. Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

 

Key Developments:

In December 2018 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

Ovarian Cancer Treatment Market

MARKET SUMMARY
-
7.1%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.1%
  • Largest Market– Europe
  • Fastest Growing Market– North-America

Ovarian Cancer Treatment Market

  • The global ovarian cancer treatment market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global market gives historical, current, and future market sizes (US$ Mn) on the basis of type of cancer, drug class, distribution channel and region.
Key Players
  • Eli Lilly and Company
  • Johnson & Johnson Services,
  • Novogen Limited
  • Aeterna Zentaris Inc.
  • GlaxoSmithKline plc
Ovarian Cancer Treatment Market Growth

Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.


North-America Got Significant Share

Ovarian Cancer Treatment Market

Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Ovarian Cancer Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Ovarian Cancer Treatment Market Introduction
2.1. Global Ovarian Cancer Treatment Market – Taxonomy
2.2. Global Ovarian Cancer Treatment Market –Definitions
2.2.1. Drug Class
2.2.2. Cancer Type
2.2.3. Distribution Channel
2.2.4. Region
3. Global Ovarian Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ovarian Cancer Treatment Market Dynamic Factors – Impact Analysis
3.6. Ovarian Cancer Epidemiology
3.7. Pipeline Analysis
3.8. Target or Mechanism of Action Analysis
3.9. Patient Journey
3.10.  Collaborations, Distribution Agreements, and Acquisitions
4. Global Ovarian Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ovarian Cancer Treatment Market, By Drug Class, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Chemotherapeutic Agents
5.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Targeted Therapy Drugs
5.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immune System Modulators
5.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Hormones
5.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Ovarian Cancer Treatment Market Forecast, By Cancer Type, 2017- 2021 and Forecast, 2022 – 2028
6.1. Epithelial Ovarian Tumor
6.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Ovarian Germ Cell Tumor
6.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Ovarian Stomatal Tumor
6.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Primary Peritoneal Carcinoma
6.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Ovarian Cancer Treatment Market, By Distribution Channel, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Ovarian Cancer Treatment Market Forecast, By Region, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Region, 2022 – 2028
9. North America Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Chemotherapeutic Agents
9.1.2. Targeted Therapy Drugs
9.1.3. Immune System Modulators
9.1.4. Hormones
9.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Epithelial Ovarian Tumor
9.2.2. Ovarian Germ Cell Tumor
9.2.3. Ovarian Stomatal Tumor
9.2.4. Primary Peritoneal Carcinoma
9.2.5. Others
9.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Others
9.4. Country Analysis 2017 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, and Country, 2022 – 2028
9.6. North America Ovarian Cancer Treatment Market Dynamics – Trends
10. Europe Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Chemotherapeutic Agents
10.1.2. Targeted Therapy Drugs
10.1.3. Immune System Modulators
10.1.4. Hormones
10.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Epithelial Ovarian Tumor
10.2.2. Ovarian Germ Cell Tumor
10.2.3. Ovarian Stomatal Tumor
10.2.4. Primary Peritoneal Carcinoma
10.2.5. Others
10.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Others
10.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. Spain
10.4.4. France
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel and Country, 2022 – 2028
10.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends
11. Asia-Pacific Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Chemotherapeutic Agents
11.1.2. Targeted Therapy Drugs
11.1.3. Immune System Modulators
11.1.4. Hormones
11.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Epithelial Ovarian Tumor
11.2.2. Ovarian Germ Cell Tumor
11.2.3. Ovarian Stomatal Tumor
11.2.4. Primary Peritoneal Carcinoma
11.2.5. Others
11.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Others
11.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Rest of Asia-Pacific
11.5. Asia-Pacific Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028
11.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends
12. Latin America Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Chemotherapeutic Agents
12.1.2. Targeted Therapy Drugs
12.1.3. Immune System Modulators
12.1.4. Hormones
12.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Epithelial Ovarian Tumor
12.2.2. Ovarian Germ Cell Tumor
12.2.3. Ovarian Stomatal Tumor
12.2.4. Primary Peritoneal Carcinoma
12.2.5. Others
12.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Others
12.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028
12.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends
13. Middle East and Africa Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Chemotherapeutic Agents
13.1.2. Targeted Therapy Drugs
13.1.3. Immune System Modulators
13.1.4. Hormones
13.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Epithelial Ovarian Tumor
13.2.2. Ovarian Germ Cell Tumor
13.2.3. Ovarian Stomatal Tumor
13.2.4. Primary Peritoneal Carcinoma
13.2.5. Others
13.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Others
13.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028
13.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Eli Lilly and Company
14.2.2. Johnson & Johnson Services, Inc.
14.2.3. Kazia Therapeutics
14.2.4. Aeterna Zentaris Inc
14.2.5. GlaxoSmithKline plc
14.2.6. F. Hoffmann-La Roche AG
14.2.7. AbbVie Inc.,
14.2.8. Pfizer Inc.,
14.2.9. AstraZeneca plc
14.2.10. Immunogen
14.2.11. Novartis
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Johnson & Johnson Services Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Novogen Limited (Australia)
  • Aeterna Zentaris Inc. (U.S)
  • GlaxoSmithKline plc (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • F. Hoffmann-La Roche AG (Switzerland)

Description

Ovarian Cancer Treatment Market size was valued at 2.2 billion in 2021 and is expected to reach 3.6 billion by 2028, at a CAGR of 7.1% during the forecast period 2022 to 2028. Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer. Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

 

Key Developments:

In December 2018 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX